AbbVie has submitted regulatory applications in the US and Europe for Rinvoq as a potential first systemic therapy for non ...
AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...
AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ® ...
AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...
AbbVie on Tuesday said the applications with the U.S. Food and Drug Administration and the European Medicines Agency cover Rinvoq for the treatment of adults and adolescents with non-segmental ...
LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...
Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...
The FDA approved ruxolitinib cream 1.5% (Opzelura) for non-segmental vitiligo in adults and children 12 years and older, making it the only FDA-approved treatment for repigmentation in vitiligo and ...
(RTTNews) - AbbVie (ABBV) announced Thursday that its Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo or NSV met the primary endpoint. Based on the data, the ...
A condition that causes the skin to lose pigmentation, vitiligo affects around one per cent of the UK population. The long-term disorder, in which white patches of skin appear on different parts of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results